Clinical trials: Haematological Malignancies
Haematological Malignancy, Leukemia
Continuous Temperature Monitoring for tHe Early Recognition of Febrile Neutropenia in Haematological MALignancies
The THERMAL study is a pilot study to determine feasibility of using two separate continuous skin temperature monitors during intensive treatment for haematological malignancies.
- Conditions
- Haematological Malignancy, Leukemia, Lymphoma, Myeloma
- Trial name
- THERMAL (NCT05203809)
- Testing
- TempTraq temperature monitor
- Where
- New Zealand
- Volunteers
- 20 people
- Sponsor
- Malaghan Institute of Medical Research
Chronic Lymphocytic Leukemia, Haematological Malignancy
variaTIon in Referral Thresholds in the Chronic Lymphocytic LeukaEmia Pathway
This study will use surveys within primary and secondary care to explore referral patterns and healthcare professional (HCP) decision-making and advice for haematological malignancies, identify inequalities, and establish best…
- Trial name
- TITLE CLL (NCT07463976)
- Where
- United Kingdom
- Volunteers
- 130 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Hematologic Malignancy, Anxiety
Cognitive-behavioural Intervention for Anxiety, Depression and Quality of Life Among Children Receiving Chemotherapy.
The diagnosis and treatment of paediatric cancer is the most stressful experience for children and their families. Nearly all paediatric cancer patients are presented with at least one psychosocial problem, of which, anxiety and…
- Conditions
- Hematologic Malignancy, Anxiety, Depression, Quality of Life
- Trial name
- NCT05270655
- Testing
- Cognitive-behavioural intervention
- Where
- 2 sites in Ethiopia
- Volunteers
- 76 people
- Sponsor
- Chinese University of Hong Kong
Haematological Malignancy, Malignancy
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
This clinical trial is looking at a drug called entrectinib. Entrectinib is approved as standard of care treatment for adult patients with non-small cell lung cancer (NSCLC) which have a particular molecular alteration called…
- Conditions
- Haematological Malignancy, Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders
- Trial name
- DETERMINE (NCT05770544)
- Testing
- Entrectinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Haematological Malignancy
Kinectics of Donor-specific Anti-HLA Antibody After HLA-incompatible Allogeneic Haematopoietic Stem Cell Transplantation
Donor specific anti-HLA antibody (DSA) is closely related not only to primary graft rejection (GR) after HLA-incompatible transplantation, but also to the occurrence of primary PGF.
- Trial name
- NCT06395220
- Testing
- Detection of donor-specific anti-HLA antibody (DSA)
- Where
- China
- Volunteers
- 314 people
- Sponsor
- Peking University People's Hospital
Solid Organ Transplant Recipients, Autoimmune Diseases
Mass Evaluation of Lateral Flow Immunoassays for the Detection of SARS-CoV-2 (Covid-19) Antibodies
DESIGN Observational epidemiological study AIMS - To determine: 1. The proportion of immunosuppressed people who have detectable SARS-CoV-2 antibodies following a primary vaccine course (3 doses), and the demographic, disease…
- Conditions
- Solid Organ Transplant Recipients, Autoimmune Diseases, Haematological Malignancies
- Trial name
- MELODY (NCT05148806)
- Testing
- self-administered lateral flow assays
- Where
- 4 sites in United Kingdom
- Volunteers
- 28,411 people
- Sponsor
- Imperial College London
Fungal Infection
Efflux Pump Mediated Azole Resistance in Candida Albicans
Candida albicans is the major fungal pathogen causing infections in humans, ranging from superficial mucosal infection to systemic mycoses.
- Trial name
- NCT03659162
- Testing
- Azole Antifungal
- Volunteers
- 100 people
- Sponsor
- Assiut University
Allogeneic Stem Cell Transplant, Graft Versus Host Disease
Nutrition and Outcomes of Hematopoietic Cell Transplantation (HCT)
Retrospective case-note review to determine if nutrition via the enteral compared to the parenteral route results in better outcomes after haematopoietic cell transplantation.
- Conditions
- Allogeneic Stem Cell Transplant, Graft Versus Host Disease, Hematologic Malignancy, Stem Cell Transplant Complications
- Trial name
- NCT03419078
- Volunteers
- 484 people
- Sponsor
- Imperial College Healthcare NHS Trust
Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child
Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant
This study will evaluate pediatric patients with malignant or non-malignant blood cell disorders who are having a blood stem cell transplant depleted of T cell receptor (TCR) alfa and beta cells that comes from a partially…
- Conditions
- Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin, Myelodysplastic Syndrome
- Trial name
- NCT02065869
- Testing
- BPX-501 T cells, Rimiducid
- Where
- 4 sites in Italy, United Kingdom
- Volunteers
- 187 people
- Sponsor
- Bellicum Pharmaceuticals
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies
Cytokine-induced killer ( CIK ) cells have been shown by our lab to be cytolytic against both autologous and allogeneic acute myeloid leukemia ( AML ) cells.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Non Hodgkin's Lymphoma
- Trial name
- alloCIK (NCT00460694)
- Testing
- infusion of allogeneic CIK cells
- Where
- Singapore
- Volunteers
- 24 people
- Sponsor
- Singapore General Hospital
Malignant Haemopathies, Acute Leukemia
Unicentric Retrospective Analysis of a Cohort of 602 Young Adult and Adolescent Patients (AJA), Aged 15 to 30 Years, With Haematological Malignancies, and Managed Between 2000 and 2016
Unicentric retrospective analysis of a cohort of 602 young adult and adolescent patients, aged 15 to 30 years, with haematological malignancies, and managed between 2000 and 2016
- Conditions
- Malignant Haemopathies, Acute Leukemia, Non-hodgkin Lymphoma, Hodgkin Lymphoma
- Trial name
- HEMAJA (NCT03469921)
- Testing
- administered therapeutic regimens
- Where
- France
- Volunteers
- 602 people
- Sponsor
- Institut Paoli-Calmettes
Acute Promyelocytic Leukemia
Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA)
The purpose of this study is to evaluate the efficacy of all-trans retinoic acid (ATRA) and idarubicin (AIDA) with a dose reduction in patients older than 70 years of age in the remission induction of acute promyelocytic leukemia…
- Trial name
- NCT00465933
- Testing
- AIDA
- Where
- 2 sites in Spain
- Sponsor
- PETHEMA Foundation
Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers
This trial investigates stem cell transplants from partially mismatched donors in patients with blood and bone marrow cancers. The trial will test two kinds of transplants - a full intensity transplant using a high dose of…
- Conditions
- Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Acute Myeloid Leukaemia, Acute Lymphoblastic Leukaemia
- Trial name
- UK-Haplo (NCT01597219)
- Testing
- Reduced intensity haplodentical stem cell transplant, Myeloablative haploidentical stem cell transplant
- Where
- 12 sites in United Kingdom
- Volunteers
- 77 people
- Sponsor
- University College, London
Central Line-associated Bloodstream Infection (CLABSI)
Hydrochloric Acid Lock Therapy for Central Line-associated Bloodstream Infections
Aim: This study will test whether treatment of central line-associated bloodstream infections (CLABSI) with hydrochloric acid lock therapy (HALT) can significantly reduce the risk of treatment failure (comprising failure to clear…
- Trial name
- NCT05376566
- Testing
- Hydrochloric Acid (2 M), Normal saline
- Where
- 4 sites in Denmark
- Volunteers
- 212 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Lymphoma, Nonhodgkin, Leukemia, Lymphocytic
Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies
CAR-T therapy is now available as a commercial product for treatment of relapsed /refractory acute lymphoblastic leukaemia and B-lymphoma. There is limited access to this new treatment as the product is very expensive.
- Trial name
- NCT06462248
- Testing
- CUCART19
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chi Kong Li
Haematological Malignancy, Colorectal Neoplasms
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
This clinical trial is looking at a combination of drugs called trastuzumab and pertuzumab. This combination of drugs is approved together as standard of care treatment for adult patients with breast cancer (often with other…
- Conditions
- Haematological Malignancy, Colorectal Neoplasms, Urinary Bladder Neoplasm, Gallbladder Neoplasms
- Trial name
- DETERMINE (NCT05786716)
- Testing
- Trastuzumab, Pertuzumab
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Haematological Malignancy, Acute Leukemia
Feasibility Study to Assess an Adapted Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Transplantation
Allogeneic haematopoietic stem cell transplantation (aHSCT) is the only curative treatment for many paediatric and young adult haematological pathologies (acute leukaemia, myelodysplastic syndromes haemoglobinopathies, bone…
- Conditions
- Haematological Malignancy, Acute Leukemia, Myelodysplastic Syndromes, Hemoglobinopathy in Children
- Trial name
- EVAADE (NCT05298930)
- Testing
- Physical activity program
- Where
- France
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Centre Leon Berard
Constipation
Ultrafast MRI Imaging to Exclude Constipation
In haematological malignancy and in immunocompromised patients, constipation is a common symptom caused by a number of factors during treatment.
- Trial name
- FIESTA (NCT02658201)
- Testing
- MRI
- Where
- United Kingdom
- Volunteers
- 11 people
- Sponsor
- Sheffield Children's NHS Foundation Trust